Logotype for Cellectar Biosciences Inc

Cellectar Biosciences (CLRB) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Cellectar Biosciences Inc

Q3 2026 earnings summary

11 Nov, 2026

Executive summary

  • Q3 progress centered on iopofosine I-131 for relapsed/refractory WM, with post-BTK inhibitor data supporting the planned accelerated-approval strategy.

  • Confirmatory Phase 3 preparation advanced, including site activation; a Phase 1b WM dosimetry study began, and CLR 125 development continued.

Financial highlights

  • Q3 2026 R&D expense was $5.44M vs. $2.5M in Q3 2025, reflecting Phase 3 preparation and increased CLR 125 trial activity.

  • Q3 2026 G&A expense was $2.67M vs. $2.3M in Q3 2025, primarily from higher professional fees and personnel costs.

  • Q3 operating expenses and operating loss were $8.10M vs. $4.85M; net loss was $7.97M vs. $4.44M, or $0.46 vs. $1.41/share.

  • 9M 2026 operating expenses were $21.09M vs. $17.29M; net loss was $20.56M vs. $16.50M, or $1.81 vs. $7.82/share.

Outlook and guidance

  • First patient dosing in the randomized Phase 3 WM trial is targeted for Q1 2027; the trial plans ~100 patients per arm, with enrollment projected to take 18–24 months after first enrollment.

  • Accelerated NDA submission is targeted for H1 2027 and may occur at or after Phase 3 initiation; enrollment must be ongoing at the FDA decision. Full approval depends on superior PFS against a comparator.

  • Phase 1b WM dosimetry is expected to assess 20–30 newly diagnosed and relapsed patients; initial CLR 125 dosimetry and safety data were expected at a Q4 2026 medical meeting.

  • CLR 225 is Phase 1-ready, but trial initiation remains subject to corporate strategy.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Cellectar Biosciences